Status:
UNKNOWN
Magnesium Sulfate for Fetal Neuroprotection
Lead Sponsor:
Cairo University
Conditions:
Fetal Neuroprotection
Eligibility:
FEMALE
18-40 years
Phase:
NA
Brief Summary
Pregnant women diagnosed to have intrapartum fetal distress (Non reassuring or pathological changes according to NICE guidelines 2017) in any of the groups will receive the allocated treatment at leas...
Detailed Description
Pregnant women diagnosed to have intrapartum fetal distress (Non reassuring or pathological changes according to NICE guidelines 2017) in any of the groups will receive the allocated treatment at leas...
Eligibility Criteria
Inclusion
- Pregnant women at least 37 week of gestation.
- Not more than 35 years old.
- Fetal distress (perinatal asphyxia) diagnosed by CTG changes (Non reassuring or pathological changes according to NICE guidelines 2017).
- Clinical chorioamnionitis.
- Prolonged rupture of membranes
Exclusion
- Medical disorders such as chronic hypertension, preeclampsia, eclampsia, DM, pulmonary hypertension, hepatic coma with risk of renal failure, and any renal, cardiac or pulmonary disease.
- RH -ve.
- Consanguinity.
- Preterm labor.
- Fetal malpresentation.
- Contraindications to the use of Magnesium Sulphate.
- Any indication for magnesium Sulphate therapy (seizure prophylaxis or tocolysis).
- Myasthenia gravis.
- Congenital fetal anomalies.
- Fetal growth restriction (birth weight \< 10th Percentile for gestational age).
- Advanced cervical dilation (8cm).
Key Trial Info
Start Date :
May 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04401852
Start Date
May 21 2020
End Date
September 1 2021
Last Update
February 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasr Alainy medical school
Cairo, Egypt, 12151